Meanwhile, patients in the UEBMI group had better liver function (albumin‐bilirubin grade I [ALBI I], p < 0.001) and lower tumor burden (α‐fetoprotein [AFP], p = 0.009; Barcelona Clinic Liver Cancer stage [BCLC], p = 0.026; Milan criteria, p < 0.001; tumor size, p < 0.001; microvascular invasion [MVI], p = 0.030; portal vein tumor thrombosis [PVTT], p = 0.002). This evidence concerns the gene ALB and liver cancer.